open access

Vol 74, No 5 (2023)
Guidelines / Expert consensus
Submitted: 2023-08-13
Accepted: 2023-08-16
Published online: 2023-10-23
Get Citation
The content of this article is also available in the following languages:
Polski

Management of hypoparathyroidism: a Position Statement of the Expert Group of the Polish Society of Endocrinology

Waldemar Misiorowski1, Marek Dedecjus2, Jerzy Konstantynowicz3, Arkadiusz Zygmunt4, Beata Kos-Kudła5, Andrzej Lewiński6, Marek Ruchała7, Wojciech Zgliczyński1
·
Pubmed: 37902011
·
Endokrynol Pol 2023;74(5):447-467.
Affiliations
  1. Department of Endocrinology, Medical Centre of Postgraduate Medical Education, Bielanski Hospital, Warsaw, Poland
  2. Department of Oncologic Endocrinology and Nuclear Medicine, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  3. Department of Pediatrics, Rheumatology, Immunology and Metabolic Bone Diseases, Medical University of Bialystok, Białystok, Poland
  4. Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Łódź, Poland
  5. Department of Endocrinology and Neuroendocrine Neoplasms, Chair of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland
  6. Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland
  7. Department of Endocrinology, Metabolism and Internal Medicine, Medical University of Poznan, Poznań, Poland

open access

Vol 74, No 5 (2023)
Guidelines
Submitted: 2023-08-13
Accepted: 2023-08-16
Published online: 2023-10-23

Abstract

Over the past few years, there have been significant advances in our understanding of hypoparathyroidism (HypoPT) in terms of its epidemiology, clinical presentation, etiology, and skeletal and renal complications. Moreover, the available treatment options for HypoPT have changed. This position statement of the Expert Group of the Polish Society of Endocrinology summarizes the current state of knowledge and provides recommendations for optimal management to assist clinicians in the diagnosis, treatment, and monitoring of HypoPT in Poland. The specific aspects of HypoPT management in children, pregnant and lactating women, and patients with chronic kidney disease are also discussed.

HypoPT is a rare disorder characterized by hypocalcemia and the lack or deficiency of parathyroid hormone (PTH). Hypoparathyroidism can be associated with complications, including nephrocalcinosis, nephrolithiasis, renal insufficiency, cataract, seizures, cardiac arrhythmia, depression, and an increased risk of infection. Minimizing complications of HypoPT requires careful evaluation and close monitoring of laboratory parameters. Conventional management of HypoPT has focused on maintaining serum calcium levels using oral calcium and active vitamin D. However, this approach is limited because it does not restore normal PTH function, is often associated with inadequate biochemical control, and raises concerns as to long-term side effects. HypoPT is the only classic endocrine insufficiency that is not commonly treated with the substitution of the missing hormone. Recently, recombinant human PTH(1-84) has become available, offering hope that the use of the missing hormone in the treatment of HypoPT will help achieve better control and reduce the risk of complications. However, this treatment is currently unavailable in Poland.

Abstract

Over the past few years, there have been significant advances in our understanding of hypoparathyroidism (HypoPT) in terms of its epidemiology, clinical presentation, etiology, and skeletal and renal complications. Moreover, the available treatment options for HypoPT have changed. This position statement of the Expert Group of the Polish Society of Endocrinology summarizes the current state of knowledge and provides recommendations for optimal management to assist clinicians in the diagnosis, treatment, and monitoring of HypoPT in Poland. The specific aspects of HypoPT management in children, pregnant and lactating women, and patients with chronic kidney disease are also discussed.

HypoPT is a rare disorder characterized by hypocalcemia and the lack or deficiency of parathyroid hormone (PTH). Hypoparathyroidism can be associated with complications, including nephrocalcinosis, nephrolithiasis, renal insufficiency, cataract, seizures, cardiac arrhythmia, depression, and an increased risk of infection. Minimizing complications of HypoPT requires careful evaluation and close monitoring of laboratory parameters. Conventional management of HypoPT has focused on maintaining serum calcium levels using oral calcium and active vitamin D. However, this approach is limited because it does not restore normal PTH function, is often associated with inadequate biochemical control, and raises concerns as to long-term side effects. HypoPT is the only classic endocrine insufficiency that is not commonly treated with the substitution of the missing hormone. Recently, recombinant human PTH(1-84) has become available, offering hope that the use of the missing hormone in the treatment of HypoPT will help achieve better control and reduce the risk of complications. However, this treatment is currently unavailable in Poland.

Get Citation

Keywords

calcium; disorders of calcium/phosphate metabolism; hypoparathyroidism; parathyroid hormone; parathyroid-related disorders; phosphate 

About this article
Title

Management of hypoparathyroidism: a Position Statement of the Expert Group of the Polish Society of Endocrinology

Journal

Endokrynologia Polska

Issue

Vol 74, No 5 (2023)

Article type

Guidelines / Expert consensus

Pages

447-467

Published online

2023-10-23

Page views

1081

Article views/downloads

3632

DOI

10.5603/ep.96950

Pubmed

37902011

Bibliographic record

Endokrynol Pol 2023;74(5):447-467.

Keywords

calcium
disorders of calcium/phosphate metabolism
hypoparathyroidism
parathyroid hormone
parathyroid-related disorders
phosphate 

Authors

Waldemar Misiorowski
Marek Dedecjus
Jerzy Konstantynowicz
Arkadiusz Zygmunt
Beata Kos-Kudła
Andrzej Lewiński
Marek Ruchała
Wojciech Zgliczyński

References (222)
  1. Khan AA, Bilezikian JP, Brandi ML, et al. International Workshop on Primary Hyperparathyroidism. The Second International Workshop on the Evaluation and Management of Hypoparathyroidism. J Bone Miner Res. 2022; 37(12): 2566–2567.
  2. Bjornsdottir S, Ing S, Mitchell D, et al. Epidemiology and Financial Burden of Adult Chronic Hypoparathyroidism. J Bone Miner Res. 2022; 37(12): 2602–2614.
  3. Pasieka JL, Wentworth K, Yeo CT, et al. Etiology and Pathophysiology of Hypoparathyroidism: A Narrative Review. J Bone Miner Res. 2022; 37(12): 2586–2601.
  4. Mannstadt M, Cianferotti L, Gafni RI, et al. Hypoparathyroidism: Genetics and Diagnosis. J Bone Miner Res. 2022; 37(12): 2615–2629.
  5. Van Uum S, Shrayyef M, M'Hiri I, et al. Initial Assessment and Monitoring of Patients with Chronic Hypoparathyroidism: A Systematic Current Practice Survey. J Bone Miner Res. 2022; 37(12): 2630–2641.
  6. Yao L, Hui Xu, Li M, et al. Complications, Symptoms, Presurgical Predictors in Patients With Chronic Hypoparathyroidism: A Systematic Review. J Bone Miner Res. 2022; 37(12): 2642–2653.
  7. Yao L, Li J, Li M, et al. Parathyroid Hormone Therapy for Managing Chronic Hypoparathyroidism: A Systematic Review and Meta-Analysis. J Bone Miner Res. 2022; 37(12): 2654–2662.
  8. Yao L, Li J, Li M, et al. Methodology for the Guidelines on Evaluation and Management of Hypoparathyroidism and Primary Hyperparathyroidism. J Bone Miner Res. 2022; 37(11): 2404–2410.
  9. Khan AA, Bilezikian JP, Brandi ML, et al. Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop. J Bone Miner Res. 2022; 37(12): 2568–2585.
  10. Bilezikian JP, Khan A, Potts JT, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011; 26(10): 2317–2337.
  11. Bilezikian JP. Hypoparathyroidism. J Clin Endocrinol Metab. 2020; 105(6): 1722–1736.
  12. Powers J, Joy K, Ruscio A, et al. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. 2013; 28(12): 2570–2576.
  13. Underbjerg L, Sikjaer T, Mosekilde L, et al. The Epidemiology of Nonsurgical Hypoparathyroidism in Denmark: A Nationwide Case Finding Study. J Bone Miner Res. 2015; 30(9): 1738–1744.
  14. Clarke BL, Brown EM, Collins MT, et al. Epidemiology and Diagnosis of Hypoparathyroidism. J Clin Endocrinol Metab. 2016; 101(6): 2284–2299.
  15. Vadiveloo T, Donnan PT, Leese CJ, et al. A Population-Based Study of the Epidemiology of Chronic Hypoparathyroidism. J Bone Miner Res. 2018; 33(3): 478–485.
  16. Kim SeH, Rhee Y, Kim YM, et al. Prevalence and complications of nonsurgical hypoparathyroidism in Korea: A nationwide cohort study. PLoS One. 2020; 15(5): e0232842.
  17. Astor MC, Løvås K, Debowska A, et al. Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway. J Clin Endocrinol Metab. 2016; 101(8): 3045–3053.
  18. Narodowy Fundusz Zdrowia, DAiI.0123.4.2021 2021.18176.CPAP. 2021.
  19. Sitges-Serra A. Etiology and Diagnosis of Permanent Hypoparathyroidism after Total Thyroidectomy. J Clin Med. 2021; 10(3).
  20. Stack BC, Bimston DN, Bodenner DL, et al. American Association of Clinical Endocrinologists and Americal College of Endocrinology disease state clinical review: postoperative hypoparathyroidism — definitions and management. Endocr Pract. 2015; 21(6): 674–685.
  21. Kazaure HS, Sosa JA. Surgical Hypoparathyroidism. Endocrinol Metab Clin North Am. 2018; 47(4): 783–796.
  22. Lorente-Poch L, Sancho JJ, Muñoz-Nova JL, et al. Defining the syndromes of parathyroid failure after total thyroidectomy. Gland Surg. 2015; 4(1): 82–90.
  23. Bollerslev J, Rejnmark L, Marcocci C, et al. European Society of Endocrinology. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015; 173(2): G1–20.
  24. Sitges-Serra A, Ruiz S, Girvent M, et al. Outcome of protracted hypoparathyroidism after total thyroidectomy. Br J Surg. 2010; 97(11): 1687–1695.
  25. Edafe O, Antakia R, Laskar N, et al. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg. 2014; 101(4): 307–320.
  26. Díez JJ, Anda E, Sastre J, et al. Prevalence and risk factors for hypoparathyroidism following total thyroidectomy in Spain: a multicentric and nation-wide retrospective analysis. Endocrine. 2019; 66(2): 405–415.
  27. Marcinkowska M, Sniecikowska B, Zygmunt A, et al. Postoperative hypoparathyroidism in patients after total thyroidectomy - retrospective analysis. Neuro Endocrinol Lett. 2017; 38(7): 488–494.
  28. Godlewska P, Benke M, Stachlewska-Nasfeter E, et al. Risk factors of permanent hypoparathyroidism after total thyroidectomy and central neck dissection for papillary thyroid cancer: a prospective study. Endokrynol Pol. 2020; 71(2): 126–133.
  29. Jørgensen CU, Homøe P, Dahl M, et al. High incidence of chronic hypoparathyroidism secondary to total thyroidectomy. Dan Med J. 2020; 67(5).
  30. Wong KP, Lang BHH. Graves' ophthalmopathy as an indication increased the risk of hypoparathyroidism after bilateral thyroidectomy. World J Surg. 2011; 35(10): 2212–2218.
  31. Kirkby-Bott J, Markogiannakis H, Skandarajah A, et al. Preoperative vitamin D deficiency predicts postoperative hypocalcemia after total thyroidectomy. World J Surg. 2011; 35(2): 324–330.
  32. Manzini G, Malhofer F, Weber T. Can preoperative vitamin D deficiency predict postoperative hypoparathyroidism following thyroid surgery? Langenbecks Arch Surg. 2019; 404(1): 55–61.
  33. Singh G, Irshaidat F, Lau C, et al. Advancing the Understanding of Vitamin D Status in Post-Thyroidectomy Hypocalcemia. Int J Endocrinol. 2021; 2021: 5598319.
  34. Vaitsi KD, Anagnostis P, Veneti S, et al. Preoperative Vitamin D Deficiency is a Risk Factor for Postthyroidectomy Hypoparathyroidism: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Endocrinol Metab. 2021; 106(4): 1209–1224.
  35. Qi Y, Chai J, Zhang L, et al. Preoperative vitamin D level is significantly associated with hypocalcemia after total thyroidectomy. BMC Musculoskelet Disord. 2022; 23(1): 1118.
  36. Ponce de León-Ballesteros G, Velázquez-Fernández D, Hernández-Calderón FJ, et al. Hypoparathyroidism After Total Thyroidectomy: Importance of the Intraoperative Management of the Parathyroid Glands. World J Surg. 2019; 43(7): 1728–1735.
  37. Lorente-Poch L, Sancho JJ, Ruiz S, et al. Importance of in situ preservation of parathyroid glands during total thyroidectomy. Br J Surg. 2015; 102(4): 359–367.
  38. Applewhite MK, White MG, Xiong M, et al. Incidence, Risk Factors, and Clinical Outcomes of Incidental Parathyroidectomy During Thyroid Surgery. Ann Surg Oncol. 2016; 23(13): 4310–4315.
  39. Park I, Rhu J, Woo JW, et al. Preserving Parathyroid Gland Vasculature to Reduce Post-thyroidectomy Hypocalcemia. World J Surg. 2016; 40(6): 1382–1389.
  40. Lang BHH, Chan DTY, Chow FCL, et al. The Association of Discolored Parathyroid Glands and Hypoparathyroidism Following Total Thyroidectomy. World J Surg. 2016; 40(7): 1611–1617.
  41. Sung TY, Lee Ym, Yoon JHo, et al. Importance of the intraoperative appearance of preserved parathyroid glands after total thyroidectomy. Surg Today. 2016; 46(3): 356–362.
  42. Falco J, Dip F, Quadri P, et al. Increased identification of parathyroid glands using near infrared light during thyroid and parathyroid surgery. Surg Endosc. 2017; 31(9): 3737–3742.
  43. McWade MA, Paras C, White LM, et al. Label-free intraoperative parathyroid localization with near-infrared autofluorescence imaging. J Clin Endocrinol Metab. 2014; 99(12): 4574–4580.
  44. Sadowski SM, Vidal Fortuny J, Triponez F. A reappraisal of vascular anatomy of the parathyroid gland based on fluorescence techniques. Gland Surg. 2017; 6(Suppl 1): S30–S37.
  45. Vidal Fortuny J, Sadowski SM, Belfontali V, et al. Randomized clinical trial of intraoperative parathyroid gland angiography with indocyanine green fluorescence predicting parathyroid function after thyroid surgery. Br J Surg. 2018; 105(4): 350–357.
  46. Barbieri D, Indelicato P, Vinciguerra A, et al. Autofluorescence and Indocyanine Green in Thyroid Surgery: A Systematic Review and Meta-Analysis. Laryngoscope. 2021; 131(7): 1683–1692.
  47. DiMarco A, Chotalia R, Bloxham R, et al. Does fluoroscopy prevent inadvertent parathyroidectomy in thyroid surgery? Ann R Coll Surg Engl. 2019; 101(7): 508–513.
  48. Di Marco AN, Palazzo FF. Near-infrared autofluorescence in thyroid and parathyroid surgery. Gland Surg. 2020; 9(Suppl 2): S136–S146.
  49. Kim SW, Song SH, Lee HS, et al. Intraoperative Real-Time Localization of Normal Parathyroid Glands With Autofluorescence Imaging. J Clin Endocrinol Metab. 2016; 101(12): 4646–4652.
  50. Benmiloud F, Rebaudet S, Varoquaux A, et al. Impact of autofluorescence-based identification of parathyroids during total thyroidectomy on postoperative hypocalcemia: a before and after controlled study. Surgery. 2018; 163(1): 23–30.
  51. Wang B, Zhu CR, Liu H, et al. The effectiveness of parathyroid gland autotransplantation in preserving parathyroid function during thyroid surgery for thyroid neoplasms: A meta-analysis. PLoS One. 2019; 14(8): e0221173.
  52. Promberger R, Ott J, Kober F, et al. Intra- and postoperative parathyroid hormone-kinetics do not advocate for autotransplantation of discolored parathyroid glands during thyroidectomy. Thyroid. 2010; 20(12): 1371–1375.
  53. Tartaglia F, Blasi S, Giuliani A, et al. Parathyroid autotransplantation during total thyroidectomy. Results of a retrospective study. Int J Surg. 2016; 28 Suppl 1: S79–S83.
  54. Zheng J, Cai S, Song H, et al. Measurement of serum intact parathyroid hormone concentration 1 day after total thyroidectomy to assess risk of permanent hypoparathyroidism. J Int Med Res. 2020; 48(6): 300060520927199.
  55. Palmhag D, Brydolf J, Zedenius J, et al. A single parathyroid hormone measurement two hours after a thyroidectomy reliably predicts permanent hypoparathyroidism. Scand J Surg. 2021; 110(3): 322–328.
  56. Lončar I, Dulfer RR, Massolt ET, et al. Postoperative parathyroid hormone levels as a predictor for persistent hypoparathyroidism. Eur J Endocrinol. 2020; 183(2): 149–159.
  57. Chang JW, Park KiW, Jung SN, et al. The most reliable time point for intact parathyroid hormone measurement to predict hypoparathyroidism after total thyroidectomy with central neck dissection to treat papillary thyroid carcinoma: a prospective cohort study. Eur Arch Otorhinolaryngol. 2020; 277(2): 549–558.
  58. Sala DT, Muresan M, Voidazan S, et al. FIRST DAY SERUM CALCIUM AND PARATHYROID HORMONE LEVELS AS PREDICTIVE FACTORS FOR SAFE DISCHARGE AFTER THYROIDECTOMY. Acta Endocrinol (Buchar). 2019; 15(2): 225–230.
  59. Calvo Espino P, Rivera Bautista JÁ, Artés Caselles M, et al. Serum levels of intact parathyroid hormone on the first day after total thyroidectomy as predictor of permanent hypoparathyroidism. Endocrinol Diabetes Nutr (Engl Ed). 2019; 66(3): 195–201.
  60. Wang W, Xia F, Meng C, et al. Prediction of permanent hypoparathyroidism by parathyroid hormone and serum calcium 24 h after thyroidectomy. Am J Otolaryngol. 2018; 39(6): 746–750.
  61. Canu GL, Medas F, Cappellacci F, et al. Intact parathyroid hormone value on the first postoperative day following total thyroidectomy as a predictor of permanent hypoparathyroidism: a retrospective analysis on 426 consecutive patients. Endokrynol Pol. 2022; 73(1): 48–55.
  62. Riordan F, Brophy C, Murphy MS, et al. Predictive value of postoperative day 1 parathyroid hormone levels for early and late hypocalcaemia after thyroidectomy. Langenbecks Arch Surg. 2022; 407(4): 1653–1658.
  63. Barczyński M, Cichoń S, Konturek A. Which criterion of intraoperative iPTH assay is the most accurate in prediction of true serum calcium levels after thyroid surgery? Langenbecks Arch Surg. 2007; 392(6): 693–698.
  64. Khan AA, Koch CA, Van Uum S, et al. Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. Eur J Endocrinol. 2019; 180(3): P1–P22.
  65. Thakker RV, Bringhurst FR, Jüppner H. Genetic disorders of calcium homeostasis caused by abnormal regulation of parathyroid hormone secretion or responsiveness. In: DeGroot LJ, Jameson JL. ed. Endocrinology. W.B. Saunders Company, Philadelphia, PA 2016: 1063–1089.
  66. Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet. 1997; 17(4): 399–403.
  67. Lankisch TO, Jaeckel E, Strassburg CP, et al. [Autoimmune polyglandular syndromes]. Internist (Berl). 2005; 46(7): 750–758.
  68. Husebye ES, Anderson MS, Kämpe O, et al. Autoimmune polyendocrine syndromes: clues to type 1 diabetes pathogenesis. Immunity. 2010; 32(4): 479–487.
  69. Brown EM. Anti-parathyroid and anti-calcium sensing receptor antibodies in autoimmune hypoparathyroidism. Endocrinol Metab Clin North Am. 2009; 38(2): 437–45, x.
  70. Kemp EH, Gavalas NG, Krohn KJE, et al. Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2009; 94(12): 4749–4756.
  71. Li Y, Song YH, Rais N, et al. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J Clin Invest. 1996; 97(4): 910–914.
  72. Goswami R, Brown EM, Kochupillai N, et al. Prevalence of calcium sensing receptor autoantibodies in patients with sporadic idiopathic hypoparathyroidism. Eur J Endocrinol. 2004; 150(1): 9–18.
  73. Raue F, Pichl J, Dörr HG, et al. Activating mutations in the calcium-sensing receptor: genetic and clinical spectrum in 25 patients with autosomal dominant hypocalcaemia - a German survey. Clin Endocrinol (Oxf). 2011; 75(6): 760–765.
  74. Carpenter TO, Carnes DL, Anast CS. Hypoparathyroidism in Wilson's disease. N Engl J Med. 1983; 309(15): 873–877.
  75. Ghosh L, Shah M, Pate S, et al. Wilson's disease presenting with hypokalemia, hypoparathyroidism and renal failure. J Assoc Physicians India. 2012; 60: 57–59.
  76. Fatima J, Karoli R, Jain V. Hypoparathyroidism in a case of Wilson's disease: Rare association of a rare disorder. Indian J Endocrinol Metab. 2013; 17(2): 361–362.
  77. Sharma R, Seth A, Chandra J, et al. Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy. Paediatr Int Child Health. 2016; 36(1): 22–27.
  78. Horwitz CA, Myers WP, Foote FW. Secondary malignant tumors of the parathyroid glands. Report of two cases with associated hypoparathyroidism. Am J Med. 1972; 52(6): 797–808.
  79. Watanabe T, Adachi I, Kimura S, et al. A case of advanced breast cancer associated with hypocalcemia. Jpn J Clin Oncol. 1983; 13(2): 441–448.
  80. Chopra D, Wool MS, Crosson A, et al. Riedel's struma associated with subacute thyroiditis, hypothyroidism, and hypoparathyroidism. J Clin Endocrinol Metab. 1978; 46(6): 869–871.
  81. Piranavan P, Li Y, Brown E, et al. Immune Checkpoint Inhibitor-Induced Hypoparathyroidism Associated With Calcium-Sensing Receptor-Activating Autoantibodies. J Clin Endocrinol Metab. 2019; 104(2): 550–556.
  82. Brown EM. PTH secretion in vivo and in vitro. Regulation by calcium and other secretagogues. Miner Electrolyte Metab. 1982; 8(3-4): 130–150.
  83. Brandi ML, Bilezikian JP, Shoback D, et al. Management of Hypoparathyroidism: Summary Statement and Guidelines. J Clin Endocrinol Metab. 2016; 101(6): 2273–2283.
  84. Shoback DM, Bilezikian JP, Costa AG, et al. Presentation of Hypoparathyroidism: Etiologies and Clinical Features. J Clin Endocrinol Metab. 2016; 101(6): 2300–2312.
  85. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008; 359(4): 391–403.
  86. Cusano NE, Bilezikian JP. Update on hypoparathyroidism. Curr Opin Rheumatol. 2019; 31(4): 381–387.
  87. Mannstadt MM, Mitchell DM. Clinical manifestations of hypoparathyroidism. In: Bilezikian JP, Marcus R, Levine MA, Marcocci C, Silverberg SJ, Potts JT. ed. The Parathyroids. Academic Press, London 2015: 761–770.
  88. Shukla S, Gillespy T, Thomas WC. The effect of hypoparathyroidism on the aging skeleton. J Am Geriatr Soc. 1990; 38(8): 884–888.
  89. Rubin MR, Rubin MR. Skeletal Manifestations of Hypoparathyroidism. Endocrinol Metab Clin North Am. 2018; 47(4): 825–837.
  90. Chawla H, Saha S, Kandasamy D, et al. Vertebral Fractures and Bone Mineral Density in Patients With Idiopathic Hypoparathyroidism on Long-Term Follow-Up. J Clin Endocrinol Metab. 2017; 102(1): 251–258.
  91. Abugassa S, Nordenström J, Eriksson S, et al. Bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab. 1993; 76(6): 1617–1621.
  92. Silva BC, Rubin MR, Cusano NE, et al. Bone imaging in hypoparathyroidism. Osteoporos Int. 2017; 28(2): 463–471.
  93. Chen Q, Kaji H, Iu MF, et al. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab. 2003; 88(10): 4655–4658.
  94. Rubin MR, Dempster DW, Zhou H, et al. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 2008; 23(12): 2018–2024.
  95. Rubin MR, Dempster DW, Kohler T, et al. Three dimensional cancellous bone structure in hypoparathyroidism. Bone. 2010; 46(1): 190–195.
  96. Dempster D. Bone histomorphometry in hypoparathyroidism. In: Brandi ML, Brown EM. ed. Hypoparathyroidism. Springer, New York, NY 2015: 287–296.
  97. Langdahl BL, Mortensen L, Vesterby A, et al. Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone. 1996; 18(2): 103–108.
  98. Fujiyama K, Kiriyama T, Ito M, et al. Attenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidism. J Clin Endocrinol Metab. 1995; 80(7): 2135–2138.
  99. Seeman E, Wahner HW, Offord KP, et al. Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest. 1982; 69(6): 1302–1309.
  100. Mendonça ML, Pereira FA, Nogueira-Barbosa MH, et al. Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density. BMC Endocr Disord. 2013; 13: 1.
  101. Cipriani C, Minisola S, Bilezikian JP, et al. Vertebral Fracture Assessment in Postmenopausal Women With Postsurgical Hypoparathyroidism. J Clin Endocrinol Metab. 2021; 106(5): 1303–1311.
  102. Underbjerg L, Sikjaer T, Mosekilde L, et al. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013; 28(11): 2277–2285.
  103. Saha S, Kandasamy D, Sharma R, et al. Nephrocalcinosis, Renal Dysfunction, and Calculi in Patients With Primary Hypoparathyroidism on Long-Term Conventional Therapy. J Clin Endocrinol Metab. 2020; 105(4).
  104. Ridder LO, Harsløf T, Sikjaer T, et al. Determinants of hypercalciuria and renal calcifications in chronic hypoparathyroidism: A cross-sectional study. Clin Endocrinol (Oxf). 2021; 95(2): 286–294.
  105. Chen KS, Gosmanova EO, Curhan GC, et al. Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84). J Clin Endocrinol Metab. 2020; 105(10): e3557–e3565.
  106. Levy I, Licht C, Daneman A, et al. The Impact of Hypoparathyroidism Treatment on the Kidney in Children: Long-Term Retrospective Follow-Up Study. J Clin Endocrinol Metab. 2015; 100(11): 4106–4113.
  107. Gosmanova EO, Chen K, Rejnmark L, et al. Risk of Chronic Kidney Disease and Estimated Glomerular Filtration Rate Decline in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. Adv Ther. 2021; 38(4): 1876–1888.
  108. Gosmanova EO, Houillier P, Rejnmark L, et al. Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism. Rev Endocr Metab Disord. 2021; 22(2): 297–316.
  109. Swartling O, Evans M, Spelman T, et al. Kidney Complications and Hospitalization in Patients With Chronic Hypoparathyroidism: A Cohort Study in Sweden. J Clin Endocrinol Metab. 2022; 107(10): e4098–e4105.
  110. Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012; 97(12): 4507–4514.
  111. Meola A, Vignali E, Matrone A, et al. Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest. 2018; 41(10): 1221–1226.
  112. Underbjerg L, Sikjaer T, Mosekilde L, et al. Postsurgical hypoparathyroidism--risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res. 2014; 29(11): 2504–2510.
  113. Underbjerg L, Sikjaer T, Rejnmark L. Long-Term Complications in Patients With Hypoparathyroidism Evaluated by Biochemical Findings: A Case-Control Study. J Bone Miner Res. 2018; 33(5): 822–831.
  114. Forman MB, Sandler MP, Danziger A, et al. Basal ganglia calcification in postoperative hypoparathyroidism. Clin Endocrinol (Oxf). 1980; 12(4): 385–390.
  115. Donzuso G, Mostile G, Nicoletti A, et al. Basal ganglia calcifications (Fahr's syndrome): related conditions and clinical features. Neurol Sci. 2019; 40(11): 2251–2263.
  116. Goswami R, Sharma R, Sreenivas V, et al. Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism. Clin Endocrinol (Oxf). 2012; 77(2): 200–206.
  117. Kar P, Millo T, Saha S, et al. Osteogenic Mechanisms of Basal Ganglia Calcification and its ex vivo Model in the Hypoparathyroid Milieu. Endocrinology. 2021; 162(4).
  118. Aggarwal S, Kailash S, Sagar R, et al. Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium. Eur J Endocrinol. 2013; 168(6): 895–903.
  119. Modi S, Tripathi M, Saha S, et al. Seizures in patients with idiopathic hypoparathyroidism: effect of antiepileptic drug withdrawal on recurrence of seizures and serum calcium control. Eur J Endocrinol. 2014; 170(5): 777–783.
  120. Phillips CG, Harnett MT, Chen W, et al. Calcium-sensing receptor activation depresses synaptic transmission. J Neurosci. 2008; 28(46): 12062–12070.
  121. Han P, Trinidad BJ, Shi J. Hypocalcemia-induced seizure: demystifying the calcium paradox. ASN Neuro. 2015; 7(2).
  122. Brown SJ, Ruppe MD, Tabatabai LS. The Parathyroid Gland and Heart Disease. Methodist Debakey Cardiovasc J. 2017; 13(2): 49–54.
  123. Bollerslev J, Sjöstedt E, Rejnmark L. Cardiovascular consequences of parathyroid disorders in adults. Ann Endocrinol (Paris). 2021; 82(3-4): 151–157.
  124. Underbjerg L, Sikjaer T, Rejnmark L. Cardiovascular findings in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism: A cohort study. Clin Endocrinol (Oxf). 2019; 90(4): 592–600.
  125. Tabacco G, Naciu AM, Maggi D, et al. Cardiovascular Autonomic Neuropathy as a New Complication of Postsurgical Chronic Hypoparathyroidism. J Bone Miner Res. 2019; 34(3): 475–481.
  126. Puliani G, Hasenmajer V, Sciarra F, et al. Impaired Immune Function in Patients With Chronic Postsurgical Hypoparathyroidism: Results of the EMPATHY Study. J Clin Endocrinol Metab. 2021; 106(5): e2215–e2227.
  127. Pohjola S. Ocular manifestations of idiopathic hypoparathyroidism. Acta Ophthalmol (Copenh). 1962; 40: 255–265.
  128. Saha S, Gantyala SP, Aggarwal S, et al. Long-term outcome of cataract surgery in patients with idiopathic hypoparathyroidism and its relationship with their calcemic status. J Bone Miner Metab. 2017; 35(4): 405–411.
  129. Arlt W, Fremerey C, Callies F, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002; 146(2): 215–222.
  130. Sikjaer T, Moser E, Rolighed L, et al. Concurrent Hypoparathyroidism Is Associated With Impaired Physical Function and Quality of Life in Hypothyroidism. J Bone Miner Res. 2016; 31(7): 1440–1448.
  131. Underbjerg L, Sikjaer T, Rejnmark L. Health-related quality of life in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism. Clin Endocrinol (Oxf). 2018; 88(6): 838–847.
  132. Büttner M, Locati LD, Pinto M, et al. Quality of Life in Patients With Hypoparathyroidism After Treatment for Thyroid Cancer. J Clin Endocrinol Metab. 2020; 105(12).
  133. Hepsen S, Akhanli P, Sakiz D, et al. The effects of patient and disease-related factors on the quality of life in patients with hypoparathyroidism. Arch Osteoporos. 2020; 15(1): 75.
  134. Brod M, Waldman LT, Smith A, et al. Assessing the Patient Experience of Hypoparathyroidism Symptoms: Development of the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom). Patient. 2020; 13(2): 151–162.
  135. Almquist M, Ivarsson K, Nordenström E, et al. Mortality in patients with permanent hypoparathyroidism after total thyroidectomy. Br J Surg. 2018; 105(10): 1313–1318.
  136. Vadiveloo T, Donnan PT, Leese CJ, et al. Increased mortality and morbidity in patients with chronic hypoparathyroidism: A population-based study. Clin Endocrinol (Oxf). 2019; 90(2): 285–292.
  137. Leibson C, Clarke BL, Ransom JE, et al. Medical care costs for persons with and without prevalent hypoparathyroidism: a population-based study (Abstract SA1071). J Bone Miner Res. 2011; 26: S183.
  138. Hadker N, Egan J, Sanders J, et al. Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. Endocr Pract. 2014; 20(7): 671–679.
  139. Chen K, Krasner A, Li N, et al. Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately vs not adequately controlled disease: a multi-country chart review. J Med Econ. 2019; 22(11): 1141–1152.
  140. Siggelkow H, Clarke BL, Germak J, et al. Burden of illness in not adequately controlled chronic hypoparathyroidism: Findings from a 13-country patient and caregiver survey. Clin Endocrinol (Oxf). 2020; 92(2): 159–168.
  141. Hamdy NAT, Decallonne B, Evenepoel P, et al. Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey. J Endocrinol Invest. 2021; 44(7): 1437–1446.
  142. Bollerslev J, Rejnmark L, Marcocci C, et al. European Society of Endocrinology. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015; 173(2): G1–20.
  143. Misiorowski W. [Badania laboratoryjne]. In: Lorenc RC, Olszyński WP. ed. [Osteoporoza. Poradnik dla lekarzy]. Wydawnictwo Biuro Gamma, Warsaw 2006: 23–26.
  144. Hannan FM, Thakker RV. Investigating hypocalcaemia. BMJ. 2013; 346: f2213.
  145. Tohme JF, Bilezikian JP. Hypocalcemic emergencies. Endocrinol Metab Clin North Am. 1993; 22(2): 363–375.
  146. Bilezikian JP, Brandi ML, Cusano NE, et al. Management of Hypoparathyroidism: Present and Future. J Clin Endocrinol Metab. 2016; 101(6): 2313–2324.
  147. Babey M, Brandi ML, Shoback D. Conventional Treatment of Hypoparathyroidism. Endocrinol Metab Clin North Am. 2018; 47(4): 889–900.
  148. Płudowski P, Kos-Kudła B, Walczak M, et al. Guidelines for Preventing and Treating Vitamin D Deficiency: A 2023 Update in Poland. Nutrients. 2023; 15(3).
  149. Sheikh MS, Santa Ana CA, Nicar MJ, et al. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med. 1987; 317(9): 532–536.
  150. Heaney RP, Dowell MS, Bierman J, et al. Absorbability and cost effectiveness in calcium supplementation. J Am Coll Nutr. 2001; 20(3): 239–246.
  151. Harvey JA, Zobitz MM, Pak CY. Dose dependency of calcium absorption: a comparison of calcium carbonate and calcium citrate. J Bone Miner Res. 1988; 3(3): 253–258.
  152. Milman S, Epstein EJ. Proton pump inhibitor-induced hypocalcemic seizure in a patient with hypoparathyroidism. Endocr Pract. 2011; 17(1): 104–107.
  153. Zaya N, Woodson G. Proton Pump Inhibitor Suppression of Calcium Absorption Presenting as Respiratory Distress in a Patient with Bilateral Laryngeal Paralysis and Hypocalcemia. Ear Nose Throat J. 2010; 89(2): 78–80.
  154. Hefti E, Trechsel U, Fleisch H, et al. Nature of calcemic effect of 1,25-dihydroxyvitamin D3 in experimental hypoparathyroidism. Am J Physiol. 1983; 244(4): E313–E316.
  155. Stamp TC. Calcitriol dosage in osteomalacia, hypoparathyroidism and attempted treatment of myositis ossificans progressiva. Curr Med Res Opin. 1981; 7(5): 316–336.
  156. Haussler MR, Whitfield GK, Haussler CA, et al. Biological activity of 1alpha-hydroxycholecalciferol, a synthetic analog of the hormonal form of vitamin D3. Proc Natl Acad Sci U S A. 1973; 70(8): 2248–2252.
  157. Halabe A, Arie R, Mimran D, et al. Hypoparathyroidism--a long-term follow-up experience with 1 alpha-vitamin D3 therapy. Clin Endocrinol (Oxf). 1994; 40(3): 303–307.
  158. Kooh SW, Fraser D, DeLuca HF, et al. Treatment of hypoparathyroidism and pseudohypoparathyroidism with metabolites of vitamin D: evidence for impaired conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D. N Engl J Med. 1975; 293(17): 840–844.
  159. Quack I, Zwernemann C, Weiner SM, et al. Dihydrotachysterol therapy for hypoparathyroidism: consequences of inadequate monitoring. Five cases and a review. Exp Clin Endocrinol Diabetes. 2005; 113(7): 376–380.
  160. Russell RG, Smith R, Walton RJ, et al. 1,25-dihydroxycholecalciferol and 1alpha-hydroxycholecalciferol in hypoparathyroidism. Lancet. 1974; 2(7871): 14–17.
  161. Kanis JA, Russell RG. Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives. Br Med J. 1977; 1(6053): 78–81.
  162. Porter RH, Cox BG, Heaney D, et al. Treatment of hypoparathyroid patients with chlorthalidone. N Engl J Med. 1978; 298(11): 577–581.
  163. Santos F, Smith MJ, Chan JC. Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide. Am J Dis Child. 1986; 140(2): 139–142.
  164. Głuszko P, Sewerynek E, Misiorowski W, et al. Guidelines for the diagnosis and management of osteoporosis in Poland. Update 2022. Endokrynol Pol. 2023; 74(1): 5–15.
  165. Sikjaer T, Rejnmark L, Rolighed L, et al. Hypoparathyroid Study Group. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011; 26(10): 2358–2370.
  166. Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013; 1(4): 275–283.
  167. Cusano NE, Rubin MR, McMahon DJ, et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2013; 98(1): 137–144.
  168. Mannstadt M, Clarke BL, Bilezikian JP, et al. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. J Clin Endocrinol Metab. 2019; 104(11): 5136–5147.
  169. Rubin MR, Cusano NE, Fan WW, et al. Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety. J Clin Endocrinol Metab. 2016; 101(7): 2742–2750.
  170. Tay YKD, Tabacco G, Cusano NE, et al. Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety. J Clin Endocrinol Metab. 2019; 104(11): 5601–5610.
  171. Tabacco G, Tay YKD, Cusano NE, et al. Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy. J Clin Endocrinol Metab. 2019; 104(7): 2748–2756.
  172. Kovacs CS. Maternal Mineral and Bone Metabolism During Pregnancy, Lactation, and Post-Weaning Recovery. Physiol Rev. 2016; 96(2): 449–547.
  173. Misiorowski W. Metabolizm wapniowy i kostny w czasie ciąży i laktacji. In: Jacha R, Jakimiuk A, Krzyczkowska-Sendrakowska A. ed. Endokrynologia ginekologiczna. Część III: Powikłania endokrynologiczne ciąży. Echokompendium, Gdynia 2022: 137–156.
  174. Schnatz PF, Curry SL. Primary hyperparathyroidism in pregnancy: evidence-based management. Obstet Gynecol Surv. 2002; 57(6): 365–376.
  175. Truong MT, Lalakea ML, Robbins P, et al. Primary hyperparathyroidism in pregnancy: a case series and review. Laryngoscope. 2008; 118(11): 1966–1969.
  176. Hatswell BL, Allan CA, Teng J, et al. Management of hypoparathyroidism in pregnancy and lactation - A report of 10 cases. Bone Rep. 2015; 3: 15–19.
  177. Khan AA, Clarke B, Rejnmark L, et al. Management of endocrine disease: Hypoparathyroidism in pregnancy: review and evidence-based recommendations for management. Eur J Endocrinol. 2019; 180(2): R37–R44.
  178. Hartogsohn EAR, Khan AA, Kjaersulf LU, et al. Changes in treatment needs of hypoparathyroidism during pregnancy and lactation: A case series. Clin Endocrinol (Oxf). 2020; 93(3): 261–268.
  179. Wang JJ, Wang Ou, Wang YB, et al. Changes in Serum Calcium and Treatment of Hypoparathyroidism During Pregnancy and Lactation: A Single-center Case Series. J Clin Endocrinol Metab. 2021; 106(12): e5054–e5063.
  180. Alikasifoglu A, Gonc EN, Yalcin E, et al. Neonatal hyperparathyroidism due to maternal hypoparathyroidism and vitamin D deficiency: a cause of multiple bone fractures. Clin Pediatr (Phila). 2005; 44(3): 267–269.
  181. Demirel N, Aydin M, Zenciroglu A, et al. Hyperparathyroidism secondary to maternal hypoparathyroidism and vitamin D deficiency: an uncommon cause of neonatal respiratory distress. Ann Trop Paediatr. 2009; 29(2): 149–154.
  182. Marcucci G, Altieri P, Benvenga S, et al. “Hypoparathyroidism Working Group” affiliated to the Italian Society of Endocrinology (S.I.E.). Hypoparathyroidism and pseudohypoparathyroidism in pregnancy: an Italian retrospective observational study. Orphanet J Rare Dis. 2021; 16(1): 421.
  183. Seki K, Osada H, Yasuda T, et al. Pseudohypoparathyroidism type 1b in pregnancy. Gynecol Obstet Invest. 1999; 47(4): 278–280.
  184. Ochiai D, Uchino H, Ikeda T, et al. Pseudohypoparathyroidism type 1a in pregnancy. J Obstet Gynaecol. 2013; 33(8): 900.
  185. Caplan RH, Wickus GG. Reduced calcitriol requirements for treating hypoparathyroidism during lactation. A case report. J Reprod Med. 1993; 38(11): 914–918.
  186. Sweeney LL, Malabanan AO, Rosen H. Decreased calcitriol requirement during pregnancy and lactation with a window of increased requirement immediately post partum. Endocr Pract. 2010; 16(3): 459–462.
  187. Gafni RI, Collins MT. Hypoparathyroidism. N Engl J Med. 2019; 380(18): 1738–1747.
  188. Barakat AJ, Raygada M, Rennert OM. Barakat syndrome revisited. Am J Med Genet A. 2018; 176(6): 1341–1348.
  189. Gylling M, Kääriäinen E, Väisänen R, et al. The hypoparathyroidism of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protective effect of male sex. J Clin Endocrinol Metab. 2003; 88(10): 4602–4608.
  190. Allgrove J, Shaw NJ. (eds.). Calcium and bone disorders in children and adolescents. 2nd revised ed. Karger, Basel (Switzerland) 2015.
  191. Hannan FM, Thakker RV. Calcium-sensing receptor (CaSR) mutations and disorders of calcium, electrolyte and water metabolism. Best Pract Res Clin Endocrinol Metab. 2013; 27(3): 359–371.
  192. Kinoshita Y, Hori M, Taguchi M, et al. Functional activities of mutant calcium-sensing receptors determine clinical presentations in patients with autosomal dominant hypocalcemia. J Clin Endocrinol Metab. 2014; 99(2): E363–E368.
  193. Demidchik YE, Demidchik EP, Reiners C, et al. Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann Surg. 2006; 243(4): 525–532.
  194. Nordenström E, Bergenfelz A, Almquist M. Permanent Hypoparathyroidism After Total Thyroidectomy in Children: Results from a National Registry. World J Surg. 2018; 42(9): 2858–2863.
  195. Wu SY, Chiang YJ, Fisher SB, et al. Risks of Hypoparathyroidism After Total Thyroidectomy in Children: A 21-Year Experience in a High-Volume Cancer Center. World J Surg. 2020; 44(2): 442–451.
  196. de Jong M, Nounou H, Rozalén García V, et al. Children are at a high risk of hypocalcaemia and hypoparathyroidism after total thyroidectomy. J Pediatr Surg. 2020; 55(7): 1260–1264.
  197. Arganbright JM, Tracy M, Feldt M, et al. Postoperative Hypocalcemia following Non-Cardiac Surgical Procedures in Children with 22q11.2 Deletion Syndrome. Genes (Basel). 2022; 13(10).
  198. Winer KK, Ye S, Ferré EMN, et al. Therapy with PTH 1-34 or calcitriol and calcium in diverse etiologies of hypoparathyroidism over 27 years at a single tertiary care center. Bone. 2021; 149: 115977.
  199. Root AW, Levine MA. One half-century of advances in the evaluation and management of disorders of bone and mineral metabolism in children and adolescents. J Pediatr Endocrinol Metab. 2023; 36(2): 105–118.
  200. Winer KK, Kelly A, Johns A, et al. Long-Term Parathyroid Hormone 1-34 Replacement Therapy in Children with Hypoparathyroidism. J Pediatr. 2018; 203: 391–399.e1.
  201. Borysewicz-Sańczyk H, Sawicka B, Michalak J, et al. Case report: a 10-year-old girl with primary hypoparathyroidism and systemic lupus erythematosus. J Pediatr Endocrinol Metab. 2020; 33(9): 1231–1235.
  202. Saraff V, Rothenbuhler A, Högler W, et al. Continuous Subcutaneous Recombinant Parathyroid Hormone (1-34) Infusion in the Management of Childhood Hypoparathyroidism Associated with Malabsorption. Horm Res Paediatr. 2018; 89(4): 271–277.
  203. Linglart A, Rothenbuhler A, Gueorgieva I, et al. Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism. J Clin Endocrinol Metab. 2011; 96(11): 3308–3312.
  204. Tuli G, Buganza R, Tessaris D, et al. Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism. Endocrine. 2020; 67(2): 457–465.
  205. Peacock M. Hypoparathyroidism and the Kidney. Endocrinol Metab Clin North Am. 2018; 47(4): 839–853.
  206. Ruospo M, Palmer SC, Natale P, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018; 8(8): CD006023.
  207. [Leczenie parykalcytolem wtórnej nadczynności przytarczyc u pacjentów hemodializowanych (ICD-10 N25.8). Załącznik B.69.]. http: //www.archiwum.mz.gov.pl/wp-content/uploads/2015/03/B.69.-nowy_od_03.2015.docx..
  208. Leczenie wtórnej nadczynności przytarczyc u pacjentów hemodializowanych (ICD-10: N25.8). Załącznik B.39. http://www.archiwum.mz.gov.pl/wp-content/uploads/2014/11/B.39._nowy-od-07.2014.docx..
  209. Eckardt KU, Kasiske BL. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; 76113(113): S1–S130.
  210. Gallo Marin B, Aghagoli G, Hu SL, et al. Calciphylaxis and Kidney Disease: A Review. Am J Kidney Dis. 2023; 81(2): 232–239.
  211. Drüeke TB, Touam M. Calcium balance in haemodialysis--do not lower the dialysate calcium concentration too much (con part). Nephrol Dial Transplant. 2009; 24(10): 2990–2993.
  212. Alfieri C, Mattinzoli D, Messa P. Tertiary and Postrenal Transplantation Hyperparathyroidism. Endocrinol Metab Clin North Am. 2021; 50(4): 649–662.
  213. Lopes MP, Kliemann BS, Bini IB, et al. Hypoparathyroidism and pseudohypoparathyroidism: etiology, laboratory features and complications. Arch Endocrinol Metab. 2016; 60(6): 532–536.
  214. Bastepe M. Genetics and epigenetics of parathyroid hormone resistance. Endocr Dev. 2013; 24: 11–24.
  215. Bastepe M, Jüppner H. Pseudohypoparathyroidism, Albright’s hereditary osteodystrophy, and progressive osseous heteroplasia: disorders caused by inactivating GNAS mutations. In: Jameson JL, DeGroot LJ. ed. Endocrinology. 7th ed. Elsevier, Philadelphia, PA 2016: 1147–1159.
  216. Lemos MC, Thakker RV. GNAS mutations in Pseudohypoparathyroidism type 1a and related disorders. Hum Mutat. 2015; 36(1): 11–19.
  217. Levine MA. An update on the clinical and molecular characteristics of pseudohypoparathyroidism. Curr Opin Endocrinol Diabetes Obes. 2012; 19(6): 443–451.
  218. Mantovani G, Bastepe M, Monk D, et al. Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nat Rev Endocrinol. 2018; 14(8): 476–500.
  219. Mantovani G. Clinical review: Pseudohypoparathyroidism: diagnosis and treatment. J Clin Endocrinol Metab. 2011; 96(10): 3020–3030.
  220. Akın L, Kurtoğlu S, Yıldız A, et al. Vitamin D deficiency rickets mimicking pseudohypoparathyroidism. J Clin Res Pediatr Endocrinol. 2010; 2(4): 173–175.
  221. Neary NM, El-Maouche D, Hopkins R, et al. Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B. J Clin Endocrinol Metab. 2012; 97(9): 3025–3030.
  222. Mouallem M, Shaharabany M, Weintrob N, et al. Cognitive impairment is prevalent in pseudohypoparathyroidism type Ia, but not in pseudopseudohypoparathyroidism: possible cerebral imprinting of Gsalpha. Clin Endocrinol (Oxf). 2008; 68(2): 233–239.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl